article · The Egyptian Journal of Hospital Medicine
Background: Autophagy is a cellular self-degradation process. Lipophagy is a selective autophagy of lipid droplets. Colorectal carcinoma has high incidence worldwide. Both sterol regulatory element-binding protein 1 (SREBP-1) and lipophagy participate in maintaining lipid homeostasis during tumor growth. Oxysterol-Binding Protein-Related Protein 8 acts as a lipophagy receptor, which interacts with microtubule-associated protein 1 light chain 3, and gamma-aminobutyric acid type A receptor-associated protein (LC3/GABARAPs). Autophagy may affect chronic inflammation and oxidative stress. Objective: This study aimed to elucidate the interplay between SREBP-1 and the lipophagy receptor oxysterol-binding protein-related protein 8 (ORP8) in colorectal carcinoma and their potential contribution in disease pathogenesis. Patients and methods: The study comprised 12 colorectal carcinoma patients, enrolled into two groups: Group 1 (having the tumor specimens), and group 2 (having their corresponding safety margin specimens). The levels of interleukin 4 (IL-4), interleukin 6 (IL-6), malondialdehyde (MDA), LC3, catalase activity, gene expression levels of SREBP-1, ORP8, and GABARAP together with immunohistochemical expression of beclin-1 were determined. Results: The current research displayed elevated gene expression levels of SREBP-1, immunohistochemical expression level of beclin 1, and protein levels of IL-4, IL-6, LC3, and MDA. Gene expression levels of ORP8, GABARAP, and catalase activity showed downregulation. There was negative relationship between SREBP-1 and ORP8 in colorectal carcinoma. Conclusion: SREBP-1 and ORP8 might contribute in disease pathogenesis.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/ejhm.2025.424798.1841
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.